Top Abstract Purchase Related
Home
>
Node
>
Subnode

Role of interferon for the treatment of myeloma

Tomita, S.; Okamoto, S.

Nihon Rinsho. Japanese Journal of Clinical Medicine 65(12): 2285-2290

2007

ISSN/ISBN: 0047-1852
PMID: 18069274
Document Number: 612292
Interferon (IFN)-alpha inhibits the growth of myeloma cell lines by inducing apoptosis. Based upon this finding, IFN has been evaluated in clinical trials as single-agent induction therapy, induction in combination with chemotherapy, and as maintenance therapy in plateau phase. Available data suggest that progression-free survival is improved with IFN, but the survival benefit is small. IFN has also been evaluated as maintenance after high-dose chemotherapy; however, the true benefit of IFN maintenance remains to be elucidated in view of conflicting data. In an area of rapidly increasing treatment options, novel agents, which have less toxicity and more biologic rationale, outweigh the limited benefits for IFN.

Document emailed within 1 workday
Secure & encrypted payments

García Laraña, J.; Díaz Mediavilla, J.; Martínez, R.; Lahuerta, J.J.; Alegre, A.; Odriozola, J.; Sureda, A.; San Miguel, J.; De la Rubia, J.; Escudero, A.; Conde, E.; Bladé, J.; Cabrera, R.; Gastearena, J.; Besalduch, J.; Vidal, M.J.; Hernández, F.; Rifon, J.; Leon, A.; Mataix, R.; Parody, R.; Moraleda, J.M.; Solano, C.; de Pablos, J.M.; Sánchez, J.J. 1997: Maintenance treatment with interferon-alfa in multiple myeloma after autotransplantation of peripheral blood progenitor cells. Spanish Register of Transplantation in Myeloma Sangre 42(Suppl 1): 38-41
Piatkowska-Jakubas, B.; Skotnicki, A.B.; Blicharski, J. 1988: Possibility of using interferon in the treatment of multiple myeloma Przeglad Lekarski 45(10): 747-750
Demina, E.A.; Votiakova, O.M. 1996: Alpha-interferon in present-day treatment of myeloma Gematologiia i Transfuziologiia 41(2): 32-36
Palumbo, A.P.; Garino, A.L.; Frieri, R.; Gallone, G.; Boccadoro, M.; Pileri, A. 1990: Consolidation treatment with dexamethasone and alpha-2B recombinant interferon further reduces the M-component level in multiple myeloma patients responding to conventional induction chemotherapy Haematologica 75(6): 576-578
Gotoh, A.; Ohyashiki, K. 2007: Role of bortezomib in the treatment of multiple myeloma Nihon Rinsho. Japanese Journal of Clinical Medicine 65(12): 2309-2314
Fermand, J.P.; Ravaud, P. 1997: Treatment of myeloma: role of intensive treatments Presse Medicale 26(11): 521-524
Kedar, I.; Segal, A. 1995: Interferon in multiple myeloma--does it pay? Israel Journal of Medical Sciences 31(10): 635-637
Gisslinger, H. 1997: Interferon alpha in the therapy of multiple myeloma Leukemia 11(Suppl 5): S52-S56
Yoshida, M.; Ohta, M.; Muroi, K.; Takeda, K.; Kitagawa, S.; Tsuboyama, A.; Sakamoto, S.; Miura, Y.; Mutoh, Y. 1984: Clinical effect of human lymphoblastoid interferon in patients with multiple myeloma Gan to Kagaku Ryoho. Cancer and ChemoTherapy 11(7): 1394-1398
Cooper, M.R. 1991: A review of the clinical studies of alpha-interferon in the management of multiple myeloma Seminars in Oncology 18(5 Suppl 7: 18-29
Liu, P.; Oken, M.; Van Ness, B. 1999: Interferon-alpha protects myeloma cell lines from dexamethasone-induced apoptosis Leukemia 13(3): 473-480
Liberati, A.M.; Cinieri, S.; Senatore, M.G.; Portuesi, M.G.; De Angelis, V.; Di Clemente, F.; Schippa, M.; Ferrajoli, A.; Arzano, S.; Berruto, P. 1990: Phase I-Ii trial on natural beta interferon in chemoresistant and relapsing multiple myeloma Haematologica 75(5): 436-442
Pisa, P.; Stenke, L.; Bernell, P.; Hansson, M.; Hast, R. 1990: Tumor necrosis factor-alpha and interferon-gamma in serum of multiple myeloma patients Anticancer Research 10(3): 817-820
Van Damme, J.; De Ley, M.; Van Snick, J.; Dinarello, C.A.; Billiau, A. 1987: The role of interferon-beta 1 and the 26-kDa protein (interferon-beta 2) as mediators of the antiviral effect of interleukin 1 and tumor necrosis factor Journal of Immunology 139(6): 1867-1872
Sumpio, B.E.; Ernstoff, M.S.; Kirkwood, J.M. 1984: Urinary excretion of interferon, albumin, and beta 2-microglobulin during interferon treatment Cancer Research 44(8): 3599-3603
Russo, D.; Fanin, R.; Zuffa, E.; Damiani, D.; Gallizia, C.; Michieli, M.; Testoni, N.; Benfenati, D.; Visani, G.; Zaccaria, A. 1990: Sequential treatment of Ph-positive chronic myeloid leukemia with interferon gamma and interferon alpha Haematologica 75(4): 334-339
Corbillet, V.; Celerier, P.; Lebon, P.; Litoux, P.; Dreno, B. 1995: Development of interferon antibodies during the treatment of skin diseases with low-dose recombinant interferon alpha-2a Annales de Medecine Interne 146(6): 399-403
Gröhn, P. 1989: Treatment of soft tissue sarcomas with interferon with special reference to general features of interferon therapy Acta Chirurgica Scandinavica. Supplementum 549: 50-51
Musch, E.; Högemann, B.; Gerritzen, A.; Fischer, H.P.; Wiese, M.; Kruis, W.; Malek, M.; Gugler, R.; Schmidt, G.; Huchzermeyer, H.; Gerlach, U.; Dengler, H.J.; Sauerbruch, T. 1998: Phase Ii clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B Hepato-Gastroenterology 45(24): 2282-2294
Guilhot, F. 1994: The role of interferon in the treatment of chronic myelogenous leukemia in chronic phase Nouvelle Revue Francaise d'Hematologie 36(Suppl 1): S39-S46